Bioheng Biotech

Main focus: Gene editing treatments

Company stage: Clinical

Diseases: T-cell acute lymphoblastic leukemia

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Nanjing, China


Bioheng Biotech is a Chinese clinical stage biotech company. The company's main focus is on developing CAR-T cells for the treatment of T-cell cancers. The company is using its proprietary Cas-V2, an optimised and safer alternative to conventional CRISPR-Cas9 systems, to avoid unwanted double stranded breaks and off-target side effects.


HashtagBioheng Biotech Co., Ltd.

Search CRISPR Medicine